Plant Name: Aglaia laxiflora
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; GPR35; | |
| PTPN1; DUSP3; PTPN2; | |
| ALPL; RECQL; AMY1A;AMY1B;AMY1C; TDP1; BLM; P4HB; AKR1B10; HPGD; AKR1B1; HSD17B10; NOX4; ALOX15; USP2; POLB; APEX1; CD38; | |
| GAA; | |
| FLT4; EPHB4; TEK; PDGFRB; INSR; AKT1; MET; PLK4; BRAF; CSNK2A1; ERBB2; MAP3K8; AURKB; EGFR; NUAK1; PLK1; KDR; GSK3B; SRC; IGF1R; AURKA; PTK2; | |
| CA2; CA12; CA13; CA5A; CA14; CA7; CA4; CA6; | |
| KDM4E; | |
| F10; | |
| BACE1; | |
| RELA; NFKB1; | |
| SLC22A6; | |
| SMAD3; LMNA; HBB; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | AMY1A;AMY1B;AMY1C | Salivary alpha-amylase | P04745 | CHEMBL2478 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
| Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
| Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
| Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | RELA | Nuclear factor NF-kappa-B p65 subunit | Q04206 | CHEMBL5533 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.174E-12 | 1.246E-09 | AKT1, AURKA, AURKB, BLM, BRAF, CSNK2A1, EGFR, EPHB4, ERBB2, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MET, NUAK1, PDGFRB, PLK1, PLK4, PTK2, RECQL, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.419E-11 | 9.973E-09 | CA12, CA13, CA2, CA4, CA5A, CA6, CA7 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 7.112E-11 | 2.346E-08 | EGFR, ERBB2, F10, INSR, MET, NOX4, PDGFRB, PTK2, SRC, TEK |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 4.765E-09 | 9.182E-07 | AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, PDGFRB, PLK1, PTK2, PTPN1, PTPN2, RELA, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.005E-08 | 1.737E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.093E-08 | 1.841E-06 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.364E-08 | 2.249E-06 | EGFR, ERBB2, INSR, KDR |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.687E-08 | 2.682E-06 | ALOX15, BRAF, EGFR, FLT4, KDR, NOX4, PDGFRB, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 2.328E-07 | 2.847E-05 | AKT1, EGFR, HBB, INSR, SMAD3 |
| MF | GO:0003824; catalytic activity | GO:0004556; alpha-amylase activity | 3.453E-07 | 4.086E-05 | AMY1A, AMY1B, AMY1C |
| MF | Unclassified; | GO:0103025; alpha-amylase activity (releasing maltohexaose) | 3.453E-07 | 4.086E-05 | AMY1A, AMY1B, AMY1C |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.094E-06 | 1.174E-04 | AKR1B1, AKT1, CD38, EGFR, KDR, PDGFRB, RELA, SLC22A6, SRC |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 2.568E-06 | 2.519E-04 | AKT1, EGFR, ERBB2, FLT4, MET, PTPN1 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.680E-06 | 2.605E-04 | CA2, CA4, EGFR, ERBB2, HPGD, SLC22A6, TEK |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 2.815E-06 | 2.712E-04 | PDGFRB, PTK2, SRC, TEK |
| BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 3.675E-06 | 3.464E-04 | EPHB4, GAA, INSR, PTK2 |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 4.172E-06 | 3.866E-04 | ADRA2C, AKT1, CD38, EGFR |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 4.716E-06 | 4.315E-04 | ADRA2C, AKT1, INSR, SRC |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 5.249E-06 | 4.723E-04 | AKR1B1, AKT1, EGFR, HPGD, PDGFRB |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 5.599E-06 | 4.997E-04 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3 |
| BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 6.667E-06 | 5.761E-04 | AKT1, CA2, PDGFRB, SRC |
| BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 7.188E-06 | 6.114E-04 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
| MF | Unclassified; | GO:0032403; protein complex binding | 9.951E-06 | 7.908E-04 | APEX1, EGFR, IGF1R, INSR, KDR, P4HB, PLK1, PTPN1, PTPN2, RELA, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.081E-05 | 8.557E-04 | APEX1, POLB |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.112E-05 | 8.768E-04 | AKT1, APEX1, AURKB, NOX4, PDGFRB, POLB, RELA |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 1.115E-05 | 8.768E-04 | AKR1B1, AKT1, CA12, CA2, CA7, CD38, EGFR, GPR35, INSR, MET, NOX4, PTPN2, SMAD3 |
| BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 1.431E-05 | 1.085E-03 | AURKA, GSK3B, HSPA1A, MET, PLK1, PLK4 |
| BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 1.534E-05 | 1.152E-03 | FLT4, KDR, PDGFRB |
| BP | GO:0050896; response to stimulus | GO:0071375; cellular response to peptide hormone stimulus | 1.591E-05 | 1.186E-03 | AKT1, APEX1, INSR, NFKB1, RELA, SRC |
| BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 1.651E-05 | 1.218E-03 | APEX1, BRAF, NOX4, RELA, TEK |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.002E-05 | 1.430E-03 | AKT1, ALPL, APEX1, BLM, EGFR, NFKB1, NOX4, SRC |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 2.322E-05 | 1.616E-03 | AKT1, HSPA1A, LMNA, RELA, SRC |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 2.543E-05 | 1.745E-03 | AKT1, AURKA, AURKB, BLM, CSNK2A1, NUAK1 |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 2.841E-05 | 1.921E-03 | AURKA, AURKB, PLK1, POLB |
| BP | GO:0050896; response to stimulus | GO:0033590; response to cobalamin | 3.235E-05 | 2.128E-03 | EGFR, RELA |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.235E-05 | 2.128E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 3.332E-05 | 2.172E-03 | AKR1B1, AKR1B10, AKT1, ALOX15, APEX1, GAA, GSK3B, HPGD, HSD17B10, KDM4E, NOX4, P4HB |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 3.602E-05 | 2.334E-03 | ADRA2C, AURKA, BRAF, EGFR, ERBB2, NFKB1, P4HB, RELA, SMAD3 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 4.910E-05 | 3.072E-03 | AKR1B1, APEX1, AURKA, CA4, EGFR, ERBB2, HSPA1A, NOX4, SRC, USP2 |
| BP | Unclassified; | GO:0006461; protein complex assembly | 5.020E-05 | 3.123E-03 | BLM, BRAF, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, PTK2, SLC22A6, SMAD3, SRC, TEK |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 5.101E-05 | 3.151E-03 | BACE1, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 5.436E-05 | 3.323E-03 | ADRA2C, AKT1, AURKA, BRAF, CA2, INSR, KDR, LMNA, NFKB1, PDGFRB, RELA, SMAD3, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 5.998E-05 | 3.578E-03 | AURKB, NOX4, PDGFRB, SRC |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 6.457E-05 | 3.831E-03 | PTPN1, PTPN2 |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 6.770E-05 | 3.974E-03 | KDR, PDGFRB, PTK2, TEK |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 6.770E-05 | 3.974E-03 | EGFR, ERBB2, MET, PDGFRB |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 7.090E-05 | 4.128E-03 | AKT1, EGFR, PLK1, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 9.521E-05 | 5.289E-03 | FLT4, KDR, PTK2, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0007586; digestion | 1.060E-04 | 5.791E-03 | AKR1B10, AMY1A, AMY1B, AMY1C |
| BP | GO:0008152; metabolic process | GO:2000630; positive regulation of miRNA metabolic process | 1.074E-04 | 5.791E-03 | NFKB1, RELA |
| MF | GO:0005488; binding | GO:0051059; NF-kappaB binding | 1.071E-04 | 5.791E-03 | APEX1, GSK3B, RELA |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.074E-04 | 5.791E-03 | BLM, RECQL |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 1.074E-04 | 5.791E-03 | AURKA, AURKB |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.192E-04 | 6.361E-03 | IGF1R, INSR, PDGFRB |
| BP | GO:0050896; response to stimulus | GO:0046627; negative regulation of insulin receptor signaling pathway | 1.321E-04 | 6.899E-03 | PTPN1, PTPN2, RELA |
| CC | GO:0043226; organelle | GO:0051233; spindle midzone | 1.459E-04 | 7.390E-03 | AURKA, AURKB, PLK1 |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.506E-04 | 7.608E-03 | AKR1B1, AKT1, EGFR, SRC |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.607E-04 | 8.027E-03 | ALOX15, HPGD |
| MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 1.607E-04 | 8.027E-03 | AURKA, AURKB |
| CC | GO:0044464; cell part | GO:0097443; sorting endosome | 1.607E-04 | 8.027E-03 | KDR, PTPN1 |
| BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 1.733E-04 | 8.540E-03 | AURKA, HSPA1A, PLK1, SMAD3, SRC, USP2 |
| MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 1.733E-04 | 8.540E-03 | EGFR, ERBB2, MET, PDGFRB, PTK2, TEK |
| BP | GO:0009987; cellular process | GO:0042058; regulation of epidermal growth factor receptor signaling pathway | 1.898E-04 | 9.145E-03 | ADRA2C, AKT1, EGFR, PTPN2 |
| BP | GO:0008283; cell proliferation | GO:0001938; positive regulation of endothelial cell proliferation | 1.898E-04 | 9.145E-03 | AKT1, FLT4, KDR, TEK |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.894E-04 | 9.145E-03 | AKR1B1, AKT1, APEX1, AURKA, AURKB, BLM, CSNK2A1, DUSP3, GSK3B, HPGD, HSPA1A, LMNA, NFKB1, NUAK1, PLK1, POLB, PTPN2, RECQL, RELA, SMAD3, SRC, USP2 |
| BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 2.014E-04 | 9.585E-03 | EPHB4, FLT4, KDR, PDGFRB, PTK2, TEK |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.021E-04 | 9.585E-03 | ADRA2C, EGFR, EPHB4, ERBB2, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, PDGFRB, TEK |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.828E-17 | 2.610E-13 | CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.733E-14 | 1.797E-11 | CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7, HBB |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.659E-16 | 2.605E-14 | CA12; CA2; CA5A; CA4; CA7; CA6; CA14; CA13 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.683E-12 | 9.626E-11 | PDGFRB; GSK3B; SRC; FLT4; ERBB2; KDR; AKT1; BRAF; MET; PTK2; EGFR; IGF1R |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.839E-12 | 9.626E-11 | PTPN1; SMAD3; CSNK2A1; SRC; INSR; ERBB2; MET; EGFR; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.019E-11 | 4.000E-10 | PDGFRB; GSK3B; ERBB2; AKT1; BRAF; RELA; EGFR; NFKB1; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.923E-11 | 1.546E-09 | PDGFRB; GSK3B; INSR; FLT4; PTK2; RELA; EGFR; NFKB1; IGF1R; KDR; AKT1; TEK; MET |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 6.327E-11 | 1.656E-09 | PDGFRB; SRC; INSR; FLT4; KDR; AKT1; BRAF; TEK; MET; EGFR; IGF1R |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.386E-10 | 3.108E-09 | PDGFRB; INSR; FLT4; KDR; AKT1; TEK; MET; RELA; EGFR; NFKB1; IGF1R |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.108E-09 | 6.450E-08 | PDGFRB; GSK3B; SMAD3; ERBB2; AKT1; BRAF; MET; EGFR; NFKB1; PTK2; RELA; IGF1R |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.646E-09 | 2.871E-08 | SMAD3; ERBB2; AKT1; BRAF; RELA; EGFR; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.310E-09 | 2.570E-08 | INSR; ERBB2; AKT1; TEK; RELA; EGFR; NFKB1; IGF1R |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.628E-08 | 1.966E-07 | SRC; ERBB2; KDR; AKT1; BRAF; MET; PTK2; EGFR; IGF1R |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.001E-08 | 1.429E-07 | PLK4; SMAD3; INSR; PLK1; AKT1; BRAF; EGFR; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.172E-08 | 1.533E-07 | GSK3B; SRC; ERBB2; AKT1; BRAF; EGFR; PTK2 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.156E-07 | 1.210E-06 | PDGFRB; DUSP3; AKT1; BRAF; MAP3K8; RELA; EGFR; NFKB1; HSPA1A |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.028E-07 | 1.153E-06 | PDGFRB; AKT1; BRAF; MET; EGFR; IGF1R |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.323E-06 | 1.222E-05 | PTPN1; GSK3B; INSR; AKT1; RELA; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 6.623E-07 | 6.499E-06 | GSK3B; ERBB2; AKT1; BRAF; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.039E-06 | 1.778E-05 | PDGFRB; AKT1; BRAF; EGFR; IGF1R |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.212E-06 | 1.828E-05 | GSK3B; SRC; AKT1; BRAF; RELA; NFKB1; PTK2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.687E-06 | 2.412E-05 | GSK3B; CSNK2A1; AKT1; CD38; RELA; NFKB1; HSPA1A |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.372E-06 | 1.862E-05 | PDGFRB; ERBB2; AKT1; MET; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.394E-06 | 2.412E-05 | GSK3B; SRC; AKT1; RELA; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.554E-06 | 1.909E-05 | SRC; MET; RELA; EGFR; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.635E-06 | 2.412E-05 | SMAD3; AKT1; BRAF; RELA; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.220E-06 | 2.650E-05 | GSK3B; AKT1; BRAF; RELA; EGFR; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.800E-06 | 2.899E-05 | GSK3B; CSNK2A1; AKT1; RELA; NFKB1; HSPA1A |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.865E-05 | 9.444E-05 | SMAD3; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.819E-05 | 9.444E-05 | PDGFRB; POLB; GSK3B; SMAD3; AKT1; RELA; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.262E-05 | 6.969E-05 | INSR; AKT1; RELA; NFKB1; IGF1R |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.062E-05 | 1.012E-04 | GSK3B; AKT1; MAP3K8; RELA; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.378E-05 | 1.131E-04 | HPGD; MET; RELA; NFKB1; PTK2; IGF1R |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.109E-05 | 1.744E-04 | GSK3B; AKT1; BRAF; RELA; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.044E-04 | 3.810E-04 | SMAD3; SRC; AKT1; RELA; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.223E-04 | 4.266E-04 | GSK3B; INSR; AKT1; RELA; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 8.275E-05 | 3.169E-04 | PTPN1; GSK3B; INSR; AKT1; BRAF |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.091E-05 | 1.386E-04 | ERBB2; AKT1; BRAF; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 8.834E-06 | 5.137E-05 | SRC; ERBB2; BRAF; EGFR |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.433E-04 | 7.958E-04 | GSK3B; AKT1; RELA; NFKB1; HSPA1A |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.316E-05 | 1.446E-04 | AKT1; BRAF; RELA; NFKB1 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 3.091E-05 | 1.386E-04 | AMY1A; AMY1B; GAA; AMY1C |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 4.339E-05 | 1.793E-04 | SRC; KDR; AKT1; PTK2 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 8.794E-05 | 3.287E-04 | GSK3B; AKT1; RELA; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.287E-05 | 6.969E-05 | AMY1A; AMY1B; AMY1C; AKT1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 5.245E-05 | 2.059E-04 | INSR; AKT1; HSPA1A; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.085E-04 | 9.497E-04 | SMAD3; AKT1; RELA; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.627E-05 | 1.863E-04 | GSK3B; SMAD3; AKT1; BRAF |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.749E-04 | 8.808E-04 | PLK1; AKT1; BRAF; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.858E-04 | 8.974E-04 | SRC; AKT1; EGFR; HSPA1A |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.663E-04 | 5.676E-04 | AKT1; RELA; NFKB1; PTK2 |
| hsa04970 | Salivary secretion_Homo sapiens_hsa04970 | 1.899E-04 | 6.342E-04 | AMY1A; AMY1B; AMY1C; CD38 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 6.112E-04 | 1.713E-03 | PDGFRB; SRC; BRAF; PTK2; EGFR |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.709E-04 | 1.099E-03 | AKT1; MAP3K8; RELA; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.270E-04 | 1.241E-03 | AKT1; MAP3K8; RELA; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.450E-04 | 1.042E-03 | SMAD3; AKT1; RELA; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.055E-03 | 2.808E-03 | LMNA; AKT1; RELA; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.568E-04 | 1.589E-03 | AKT1; RELA; NFKB1; HSPA1A |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.172E-03 | 2.953E-03 | PDGFRB; INSR; AKT1; EGFR |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.112E-03 | 2.911E-03 | GSK3B; SMAD3; AKT1; IGF1R |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 7.339E-04 | 1.987E-03 | GSK3B; MET; PTK2; EPHB4 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.586E-03 | 3.772E-03 | PDGFRB; FLT4; KDR; MET; EGFR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.604E-03 | 5.840E-03 | PDGFRB; ERBB2; MET; EGFR; NFKB1 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 2.648E-03 | 5.855E-03 | PDGFRB; ERBB2; CD38; EGFR |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.543E-03 | 5.786E-03 | SRC; AKT1; RELA; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.793E-03 | 8.048E-03 | AKT1; BRAF; RELA; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.215E-03 | 8.594E-03 | POLB; SRC; RELA; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.709E-03 | 1.120E-02 | AKR1B10; AMY1A; GAA; AMY1B; AMY1C; ALOX15; CD38; AKR1B1; ALPL; HSD17B10 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.166E-03 | 8.594E-03 | PDGFRB; AKT1; EGFR |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 4.052E-03 | 8.482E-03 | RELA; NFKB1; PTK2 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 7.199E-03 | 1.344E-02 | PLK1; AURKA; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.421E-03 | 1.229E-02 | GSK3B; SRC; AKT1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.304E-03 | 7.105E-03 | CSNK2A1; RELA; NFKB1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.065E-02 | 1.857E-02 | GSK3B; SMAD3; CSNK2A1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.726E-03 | 1.272E-02 | AKT1; RELA; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 8.733E-03 | 1.576E-02 | AKT1; RELA; NFKB1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.004E-03 | 4.695E-03 | SRC; MET; PTK2 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 1.005E-02 | 1.793E-02 | CSNK2A1; SRC; AKT1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 7.360E-03 | 1.344E-02 | INSR; AKT1; IGF1R |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.826E-03 | 6.161E-03 | PDGFRB; SRC; EGFR |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.418E-02 | 2.368E-02 | SRC; CD38; EGFR |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 7.360E-03 | 1.344E-02 | GSK3B; SMAD3; PLK1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.468E-03 | 3.546E-03 | AKT1; RELA; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.239E-03 | 3.038E-03 | AKT1; BRAF; MET |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.642E-02 | 2.605E-02 | INSR; AKT1; ADRA2C |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.148E-02 | 3.275E-02 | CSNK2A1; RELA; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.669E-02 | 2.620E-02 | BACE1; GSK3B; HSD17B10 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.185E-03 | 2.953E-03 | SMAD3; RELA; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.185E-03 | 2.953E-03 | SRC; RELA; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 7.281E-04 | 1.987E-03 | RELA; NFKB1; HSPA1A |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 3.102E-02 | 4.594E-02 | RELA; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.290E-02 | 3.457E-02 | RELA; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.408E-02 | 3.601E-02 | RELA; NFKB1 |
| hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 2.117E-02 | 3.259E-02 | RELA; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.389E-02 | 2.345E-02 | INSR; AKT1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.584E-02 | 2.537E-02 | AKT1; BRAF |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.584E-02 | 2.537E-02 | BRAF; IGF1R |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 1.789E-02 | 2.781E-02 | RELA; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.193E-04 | 4.256E-04 | AKR1B10; GAA; AKR1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.437E-02 | 2.374E-02 | RELA; NFKB1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.534E-02 | 2.509E-02 | AKR1B10; AKR1B1 |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 1.076E-02 | 1.857E-02 | HBB; MET |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.119E-02 | 1.909E-02 | INSR; IGF1R |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.076E-02 | 1.857E-02 | RELA; NFKB1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 4.700E-03 | 9.460E-03 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.993E-03 | 9.923E-03 | POLB; APEX1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 5.921E-03 | 1.148E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.442E-03 | 5.639E-03 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; EGFR; ERBB2; PLK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PDGFRB; MET; KDR; EGFR; EGFR; IGF1R; IGF1R |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKA; PLK1; AURKB |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; EGFR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT4; TEK; PDGFRB; AURKA; AKT1; MET; KDR; KDR; KDR; SRC; EGFR; ERBB2; PLK1; PLK1; IGF1R; AURKB; PTK2 |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; CD38 |
| C00-D49: Neoplasms | AML | NA | KDR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; ADRA2C; GSK3B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10 |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | BRAF |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; INSR; NFKB1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; EGFR; EGFR; ERBB2; IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA; MET; PLK1 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ERBB2; ADRA2C |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| NA: NA | Haemophilia B | NA | F10 |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; PDGFRB; INSR; AKR1B1; GSK3B |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; ERBB2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10 |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; BRAF |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; KDR; EGFR; EGFR; EGFR; AKR1B1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
| C00-D49: Neoplasms | Breast cancer | C50 | INSR; KDR; KDR; KDR; EGFR; EGFR; EGFR; ERBB2; ERBB2; ERBB2; IGF1R |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| NA: NA | Christmas disease | NA | F10 |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR; EGFR; BRAF |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; ERBB2 |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; EGFR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; EGFR; EGFR; ERBB2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| C00-D49: Neoplasms | Solid tumors | NA | BRAF |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; EGFR |
| C00-D49: Neoplasms | Cancer | C00-C96 | FLT4; EPHB4; TEK; AURKA; AKT1; MET; KDR; SRC; NFKB1; EGFR; ERBB2; ERBB2; PLK1; GSK3B; IGF1R; CD38; BRAF; BRAF; PTK2; CSNK2A1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA; BRAF; PTK2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1 |
| C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | FLT4; MET; KDR; IGF1R |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; CD38; AURKB |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR; EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; ADRA2C; IGF1R |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; KDR; EGFR; PLK1 |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR; EGFR; EGFR; ERBB2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT4; EGFR; ERBB2; PLK1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| C00-D49: Neoplasms | Renal cancer | C64 | F10; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |